Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies

Inclusion Criteria: * Phase I: Histologically confirmed relapsed or refractory non-Hodgkin lymphoma or Hodgkin lymphoma (WHO criteria), with no accepted curative options. * Phase II: Relapsed or refractory T-cell lymphoma, including patients with central nervous system (CNS) involvement or lymphomatous meningitis are allowed on study. * Relapsed or refractory disease following frontline chemotherapy. No upper limit for the number of prior therapies. Patients may have relapsed after prior autologous or allogeneic stem cell transplant. * Evaluable Disease in the Phase I, and measurable disease for the Phase II. * Age \> or = 18 years. * Eastern Cooperative Oncology Group (ECOG) performance status \< or = 2. * Patients must have adequate organ and marrow function. * Negative urine or serum pregnancy test for females of childbearing potential. * All females of childbearing potential must use an effective barrier method of contraception during the treatment period and for at least 1 month thereafter. Male subjects should use a barrier method of contraception during the treatment period and for at least 3 months thereafter. * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Prior Therapy * Exposure to chemotherapy or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier. * Systemic steroids that have not been stabilized ( ≥ 5 days) to the equivalent of ≤10 mg/day prednisone prior to the start of the study drugs. * No other concurrent investigational agents are allowed. * History of allergic reactions to Oral 5-azacitidine or Romidepsin. * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * Pregnant women. * Nursing women. * Active concurrent malignancy (except non-melanoma skin cancer or carcinoma in situ of the cervix). If there is a history of prior malignancy, the patient must be disease-free for ≥ 3 years. * Patients known to be Human Immunodeficiency Virus (HIV)-positive. * Patients with active hepatitis A, hepatitis B, or hepatitis C infection. * Concomitant use of CYP3A4 inhibitors. * Any known cardiac abnormalities.